Your search for osteoporosis returned 151 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

News remove

Your search for osteoporosis returned 151 results

Sort Results:

Relevant Recent

USPSTF Issues Recommendations for Osteoporosis Screening

Screening for osteoporosis with bone measurement testing should also occur in postmenopausal women <65 years who are at increased risk of osteoporosis as determined by a formal clinical risk assessment tool (B recommendation).

Prolia approved for postmenopausal osteoporosis

The FDA has approved Prolia (denosumab, from Amgen) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
ACR/ARHP Annual Meeting 2015

Low Incidence of Jaw Osteonecrosis With Prolia, Bisphosphonate Tx

Treatment with Prolia (denosumab) or bisphosphonates was associated with a low incidence rate of potential osteonecrosis of the jaw among postmenopausal women with osteoporosis, according to data presented by Fei Xue, MD, Center for Observational Research, Amgen Inc, at the 2015 ACR/ARHP Annual Meeting.